229 related articles for article (PubMed ID: 27169844)
1. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
2. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
Suto H; Matsukawa H; Fuke T; Nagao M; Ando Y; Oshima M; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
Pancreatology; 2024 May; 24(3):431-436. PubMed ID: 38383175
[TBL] [Abstract][Full Text] [Related]
3. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.
Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Lee DH; Kwon W; Jang JY
Int J Surg; 2024 May; 110(5):2883-2893. PubMed ID: 38376856
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
5. Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable Pancreatic Cancer: A Retrospective Study.
Suto H; Fuke T; Matsukawa H; Ando Y; Oshima M; Nagao M; Takahashi S; Shibata T; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592055
[No Abstract] [Full Text] [Related]
6. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
[TBL] [Abstract][Full Text] [Related]
7. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.
Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z
Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767
[TBL] [Abstract][Full Text] [Related]
8. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement.
Akahori T; Terai T; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Sho M
Ann Gastroenterol Surg; 2024 Jan; 8(1):151-162. PubMed ID: 38250684
[TBL] [Abstract][Full Text] [Related]
9. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Shimokawa T; Nakao A; Yamaue H
Ann Gastroenterol Surg; 2017 Sep; 1(3):208-218. PubMed ID: 29863125
[TBL] [Abstract][Full Text] [Related]
10. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma.
Terai T; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Sho M
Pancreatology; 2023 Dec; 23(8):970-977. PubMed ID: 37914628
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.
Dhir M; Malhotra GK; Sohal DPS; Hein NA; Smith LM; O'Reilly EM; Bahary N; Are C
World J Surg Oncol; 2017 Oct; 15(1):183. PubMed ID: 29017581
[TBL] [Abstract][Full Text] [Related]
12. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition".
Belfiori G; Crippa S; Pagnanelli M; Gasparini G; Aleotti F; Camisa PR; Partelli S; Pecorelli N; De Stefano F; Schiavo Lena M; Palumbo D; Tamburrino D; Reni M; Falconi M
Ann Surg Oncol; 2024 Jun; 31(6):4084-4095. PubMed ID: 38459416
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment.
Jomrich G; Gruber M; Gruber ES; Mühlbacher J; Radosavljevic S; Wilfing L; Winkler D; Prager G; Reiterer C; Kabon B; Haslacher H; Sahora K; Schindl M
J Visc Surg; 2024 Apr; 161(2):99-105. PubMed ID: 37391288
[TBL] [Abstract][Full Text] [Related]
14. Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas.
Miyata Y; Yonamine N; Fujinuma I; Tsunenari T; Takihata Y; Hakoda H; Nakazawa A; Iwasaki T; Einama T; Togashi J; Tsujimoto H; Ueno H; Beck Y; Kishi Y
Ann Surg Oncol; 2023 Dec; 30(13):8621-8630. PubMed ID: 37658273
[TBL] [Abstract][Full Text] [Related]
15. Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma.
Akumuo RC; Reddy SP; Westwood C; Devarajan K; Barrak D; Reddy SS; Villano AM
J Gastrointest Surg; 2024 May; 28(5):605-610. PubMed ID: 38704197
[TBL] [Abstract][Full Text] [Related]
16. Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenocarcinoma.
Akumuo RC; Villano AM; Reddy SP; Devarajan K; Barrak D; Reddy SS
Am J Surg; 2024 Jun; 232():9-14. PubMed ID: 37977978
[TBL] [Abstract][Full Text] [Related]
17. The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma.
Ross SB; Popover J; Sucandy I; Christodoulou M; Pattilachan TM; Rosemurgy AS
Am Surg; 2024 Apr; ():31348241248703. PubMed ID: 38635295
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma: An Updated Nationwide Study.
Sugawara T; Rodriguez Franco S; Sherman S; Torphy RJ; Colborn K; Franklin O; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
Ann Surg; 2024 Feb; 279(2):331-339. PubMed ID: 37226812
[TBL] [Abstract][Full Text] [Related]
19. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
[TBL] [Abstract][Full Text] [Related]
20. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.
van Eijck CWF; Real FX; Malats N; Vadgama D; van den Bosch TPP; Doukas M; van Eijck CHJ; Mustafa DAM;
Cell Rep Med; 2024 May; 5(5):101557. PubMed ID: 38733987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
